BEAM Valuation

Beam Therapeutics Inc

Add to Watchlist

Advanced Chart

16.360

-0.49(-2.908%)1D

Overview
Forecast
Valuation
Earnings

BEAM Relative Valuation

BEAM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BEAM is overvalued; if below, it's undervalued.

Historical Valuation

Beam Therapeutics Inc (BEAM) is now in the Fair zone, suggesting that its current forward PS ratio of 27.06 is considered Fairly compared with the five-year average of -11.17. The fair price of Beam Therapeutics Inc (BEAM) is between 15.27 to 19.77 according to relative valuation methord.

Relative Value

Fair Zone

15.27-19.77

Current Price：16.53

Fair

-4.11

Trailing

Forward

-1.46

EV/EBITDA

Beam Therapeutics Inc. (BEAM) has a current EV/EBITDA of -1.46. The 5-year average EV/EBITDA is -9.19. The thresholds are as follows: Strongly Undervalued below -28.01, Undervalued between -28.01 and -18.60, Fairly Valued between 0.22 and -18.60, Overvalued between 0.22 and 9.63, and Strongly Overvalued above 9.63. The current Forward EV/EBITDA of -1.46 falls within the Historic Trend Line -Fairly Valued range.

-1.35

EV/EBIT

Beam Therapeutics Inc. (BEAM) has a current EV/EBIT of -1.35. The 5-year average EV/EBIT is -8.34. The thresholds are as follows: Strongly Undervalued below -24.86, Undervalued between -24.86 and -16.60, Fairly Valued between -0.08 and -16.60, Overvalued between -0.08 and 8.17, and Strongly Overvalued above 8.17. The current Forward EV/EBIT of -1.35 falls within the Historic Trend Line -Fairly Valued range.

27.06

Beam Therapeutics Inc. (BEAM) has a current PS of 27.06. The 5-year average PS is 3340.65. The thresholds are as follows: Strongly Undervalued below -44938.84, Undervalued between -44938.84 and -20799.10, Fairly Valued between 27480.39 and -20799.10, Overvalued between 27480.39 and 51620.13, and Strongly Overvalued above 51620.13. The current Forward PS of 27.06 falls within the Historic Trend Line -Fairly Valued range.

-9.81

P/OCF

Beam Therapeutics Inc. (BEAM) has a current P/OCF of -9.81. The 5-year average P/OCF is -16.73. The thresholds are as follows: Strongly Undervalued below -50.15, Undervalued between -50.15 and -33.44, Fairly Valued between -0.03 and -33.44, Overvalued between -0.03 and 16.68, and Strongly Overvalued above 16.68. The current Forward P/OCF of -9.81 falls within the Historic Trend Line -Fairly Valued range.

-8.56

P/FCF

Beam Therapeutics Inc. (BEAM) has a current P/FCF of -8.56. The 5-year average P/FCF is -11.92. The thresholds are as follows: Strongly Undervalued below -28.11, Undervalued between -28.11 and -20.01, Fairly Valued between -3.83 and -20.01, Overvalued between -3.83 and 4.27, and Strongly Overvalued above 4.27. The current Forward P/FCF of -8.56 falls within the Historic Trend Line -Fairly Valued range.

Beam Therapeutics Inc (BEAM) has a current Price-to-Book (P/B) ratio of 1.58. Compared to its 3-year average P/B ratio of 2.74 , the current P/B ratio is approximately -42.48% higher. Relative to its 5-year average P/B ratio of 5.53, the current P/B ratio is about -71.53% higher. Beam Therapeutics Inc (BEAM) has a Forward Free Cash Flow (FCF) yield of approximately -21.46%. Compared to its 3-year average FCF yield of -10.74%, the current FCF yield is approximately 99.82% lower. Relative to its 5-year average FCF yield of -6.99% , the current FCF yield is about 207.15% lower.

1.58

P/B

Median3y

2.74

Median5y

5.53

-21.46

FCF Yield

Median3y

-10.74

Median5y

-6.99

Competitors Valuation Multiple

The average P/S ratio for BEAM's competitors is 12.26, providing a benchmark for relative valuation. Beam Therapeutics Inc Corp (BEAM) exhibits a P/S ratio of 27.06, which is 120.72% above the industry average. Given its robust revenue growth of -28.08%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

BEAM.O

Beam Therapeutics Inc

Cogent Biosciences Inc

Loss

1.70B

IMCR.O

Immunocore Holdings PLC

Twist Bioscience Corp

WAVE Life Sciences Ltd

Aurinia Pharmaceuticals Inc

5.61

22.41%

1.58B

Performance Decomposition

Market capitalization of BEAM decreased by 36.84% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -773.45 to -1.21K.

The secondary factor is the Revenue Growth, contributed -28.08%to the performance.

Overall, the performance of BEAM in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-28.08%

11.77M → 8.47M

Revenue Growth

56.22%

-773.45 → -1.21K

Margin Expansion

-64.98%

-10.40 → -3.64

P/E Change

-36.84%